patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus standard of care - for COVID 19 outpatients
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.42 [0.01, 12.75]< 1 0% 1 study (1/-) 68.7 % NA not evaluable crucial - deaths 1.33 [0.34, 5.28]< 1 0% 7 studies (7/-) 34.2 % some concern not evaluable moderate crucial - hospitalization or death 0.85 [0.63, 1.14]< 1 0% 3 studies (3/-) 86.4 % some concern not evaluable moderate crucial - A EFFACER PCR-negative (end of follow-up) 0.91 [0.57, 1.46]> 1 0% 1 study (1/-) 34.7 % NA not evaluable important - clinical deterioration 0.25 [0.07, 0.84]< 1 0% 2 studies (2/-) 98.8 % high not evaluable low important - clinical improvement 1.15 [1.06, 1.26]> 1 0% 5 studies (5/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.50 [0.69, 3.24]> 1 0% 1 study (1/-) 84.7 % NA not evaluable important - clinical improvement (28-day) 8.71 [1.99, 38.12]> 1 0% 1 study (1/-) 99.8 % NA not evaluable important - clinical improvement (7-day) 3.14 [0.60, 16.38]> 1 0% 1 study (1/-) 91.2 % NA not evaluable important - clinical improvement (time to event analysis only) 1.08 [0.95, 1.23]> 1 0% 1 study (1/-) 87.9 % NA not evaluable important - hospitalization 0.95 [0.66, 1.38]< 1 0% 8 studies (8/-) 59.7 % some concern not evaluable moderate important - mechanical ventilation 0.88 [0.42, 1.85]< 1 0% 2 studies (2/-) 62.8 % some concern not evaluable moderate important - viral clearance 0.47 [0.04, 5.69]> 1 0% 1 study (1/-) 27.9 % NA not evaluable important - ICU admission 0.59 [0.29, 1.18]< 1 0% 2 studies (2/-) 93.2 % some concern not evaluable moderate non important - recovery 1.08 [0.83, 1.40]> 1 75% 2 studies (2/-) 70.8 % some concern not evaluable moderate non important - 00 adverse events 178.20 [73.71, 430.85]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important -
LoD: level of statistical demonstration:
